Targeting the HER2 receptor in metastatic breast cancer

Hematology/ Oncology and Stem Cell Therapy

Volumn 5, Issue 3, 2012, Pages 127-137

  Orphanos, George ^a   Kountourakis, Panteleimon ^b  

^a Ygia Polyclinic   (Cyprus)

^b Bank of Cyprus Group Oncology Centre   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANASTROZOLE; ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOKERATIN 5; CYTOKERATIN 6; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERTUMAXOMAB; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GOSERELIN; LAPATINIB; LETROZOLE; NERATINIB; PACLITAXEL; PERTUZUMAB; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN METASTASIS; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; DIARRHEA; DRUG APPROVAL; DRUG DESIGN; DRUG ERUPTION; DRUG RESEARCH; DRUG TARGETING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GENE MUTATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; IN VIVO STUDY; INFLAMMATORY BREAST CANCER; LOADING DRUG DOSE; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN FAMILY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; VOMITING;

EID: 84875433338     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2012.127     Document Type: Review

References (100)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29.
2. van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol.1994;10:251.
3. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med.2005;355;172-187.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74.
5. Henningsen B. Clinical experiences with tamoxifen for estrogen receptor blocking therapy in metastatic breast cancer. Prog Clin Biol Res. 1977;12:479-82.
6. Fisher ER, Costantino J, Fisher B et al. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer. 1993 Mar 15;71(6 Suppl):2141-50.
7. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005 Oct 10;23(29):7350-60.
8. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74.
9. Valentin MD, da Silva SD, Privat M et al. Molecular insights on basal-like breast cancer. Breast Cancer Res Treat. 2012 Jul;134(1):21-30.
10. Blows FM, Driver KE, Schmidt MK et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010 May 25;7(5):e1000279.
11. Marcus JN, Watson P, Page DL et al. Hereditary breast cancer: pathobiology, prognosis, and BR CA1 and BR CA2 gene linkage. Cancer. 1996 Feb 15;77(4): 697-709.
12. Collins LC, Martyniak A, Kandel MJ et al Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BR CA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol. 2009 Jul;33 (7):1093-7.
13. Bal A, Verma S, Joshi K et al. BR CA1-methylated sporadic breast cancers are BR CA-like in showing a basal phenotype and absence of ER expression. Virchows Arch. 2012 Jul 21.
14. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37.
15. Normanno N, Bianco C, Strizzi L. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets. 2005 May;6(3):243-57.
16. Serra V, Scaltriti M, Prudkin L et al. PI 3K inhibition results in enhanced HER signaling and acquired ER K dependency in HER 2-overexpressing breast cancer. Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626
17. Hynes NE, Stern DF. The biology of erbB-2/neu/ HER 2 and its role in cancer. Biochim Biophys Acta. 1994 Dec 30;1198(2-3):165-84.
18. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER 2/neu oncogene. Science. 1987 Jan 9;235(4785):177-82.
19. Yarden Y. The EG FR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8.
20. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem. 1996 Mar 1;271(9):5251-7.
21. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70.
22. Bilous M, Dowsett M, Hanna W et al. Current perspectives on HER 2 testing: a review of national testing guidelines. Mod Pathol. 2003 Feb;16(2):173-82.
23. Penault-Llorca F, Bilous M, Dowsett M et al. Emerging technologies for assessing HER 2 amplification. Am J Clin Pathol. 2009 Oct;132(4):539-48.
24. Tsé C, Gauchez AS, Jacot W, Lamy PJ. HER 2 shedding and serum HER 2 extracellular domain: Biology and clinical utility in breast cancer. Cancer Treat Rev. 2011.
25. Ardavanis A, Kountourakis P, Kyriakou F et al. Trastuzumab plus paclitaxel or docetaxel in HER 2-negative/HER 2 ECD-positive anthracycline-and taxane-refractory advanced breast cancer. Oncologist. 2008 Apr;13(4):361-9.
26. Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER 2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285-9.
27. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER 2 monoclonal antibody has antiproliferative effects in vitro and sen-sitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989;9(3):1165-72.
28. Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER 2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259-67.
29. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001;61(12):4744-9.
30. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. 1985;41(3):697-706.
31. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-48.
32. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-26.
33. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
34. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722-30.
35. Bartsch R, Wenzel C, Altorjai G et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25(25):3853-8.
36. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265-74.
37. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19(10):2587-95.
38. Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev. 2004;30(1):53-81.
39. Konecny GE, Pegram MD. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. Oncology (Williston Park). 2004;18(14 Suppl 12):32-6.
40. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-21.
41. Buzdar AU, Valero V, Ibrahim NK et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13(1):228-33.
42. Waddell T, Kotsori A, Constantinidou A et al. Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience. Br J Cancer. 2011;104(11):1675-9.
43. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27(12):1999-2006.
44. Bartsch R, De Vries C, Pluschnig U et al. Predicting for activity of second-line trastuzumabbased therapy in her2-positive advanced breast cancer. BMC Cancer. 2009;9:367.
45. Montemurro F, Redana S, Viale G et al. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. Clin Breast Cancer. 2008;8(5):436-42.
46. Nahta R, Yuan LX, Zhang B, et al. Insulinlike growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65:11118-11128.
47. Scaltriti M, Rojo F, Ocaña A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628-38.
48. Kozloski GA, Carraway CA, Carraway KL. Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity. J Cell Physiol. 2010;224(3):649-57.
49. Razis E, Bobos M, Kotoula V et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011;128(2):447-56.
50. Vazquez-Martin A, Colomer R, Brunet J et al: Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int J Oncol. 2007;31:769-776.
51. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004;64(11):3981-6.
52. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumabbased therapy in patients with HER2/neu-positive metastatic breast cancer. J Clin Oncol. 2008 10;26(11): 1789-96.
53. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004;64(11):3981-6.
54. Rusnak DW, Affleck K, Cockerill SG et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001;61(19):7196-203.
55. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002;21(41):6255-63.
56. Rusnak DW, Lackey K, Affleck K et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001; 1(2):85-94.
57. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER2-overexpressing and trastuzumab treated breast cancer cells. Cancer Res 2006;66(3):1630-1639.
58. Tomasello G, Bedard PL, de Azambuja E, Lossignol D, Devriendt D, Piccart-Gebhart MJ. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Crit Rev Oncol Hematol. 2010;75(2):110-21.
59. Moy B, Kirkpatrick P, Kar S, Goss P. Lapatinib. Nat Rev Drug Discov. 2007;6(6):431-2.
60. Burstein HJ, Storniolo AM, Franco S et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008;19(6):1068-74.
61. Gomez HL, Doval DC, Chavez MA et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26(18):2999-3005.
62. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355 (26): 2733-43.
63. Di Leo A, Gomez HL, Aziz Z et al. Phase II, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26(34):5544-52.
64. Kaufman B, Trudeau M, Awada A et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol. 2009;10(6):581-8.
65. O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J. Synergistic interaction between trastuzumab and EGFR/HER2 tyrosine kinase inhibitors in HER2 positive breast cancer cells. Invest New Drugs. 2011;29(5):752-9.
66. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-30.
67. Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER 2/Neu-Positive Metastatic Breast Cancer(NCT00667251).
68. Continued HER 2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone (NCT00968968).
69. Brufsky AM, Mayer M, Rugo HS et al. Central nervous system metastases in patients with HER 2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834-43.
70. Montagna E, Cancello G, D'Agostino D et al. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. Cancer Chemother Pharmacol. 2009;63(2):275-80.
71. Lin NU, Diéras V, Paul D, Lossignol D et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER 2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-9.
72. Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER 2 Positive Breast Cancer (LAP TEM). NCT00614978.
73. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29(2):217-33.
74. De Laurentiis M, Arpino G, Massarelli E et al. A meta-analysis on the interaction between HER 2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 20051;11(13):4741-8.
75. Kaufman B, Mackey JR, Clemens MR Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAn-DE M study. J Clin Oncol. 2009;27(33):5529-37.
76. Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER 2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15(2):122-9.
77. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER 2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290.
78. Franklin MC, Carey KD, Vajdos FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 317-328.
79. Rabindran SK, Discafani CM, Rosfjord EC et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER 2 tyrosine kinase. Cancer Res 2004; 64: 3958-3965.
80. Li D, Ambrgio L, Shimamura T et al. BIB W2992, an irreversible EG FR/HER 2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27: 4702-4711.
81. Nielsen DL, Andersson M, Kamby C. HER 2-targeted therapy in breast cancer: monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35: 121-136.
82. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, a HER 2 antibody-drug conjugate, given every 3 weeks to patients with HER 2-positive metastatic breast cancer. J Clin Oncol 2010; 28: 398-405.
83. Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23: 2534-2543.
84. Wonk KK, Fracasso PM, Bukowski RM et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009; 15: 2552-2558.
85. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EG FR and HER 2 kinase inhibitor BIB W 2992 in patients with advanced solid tumors. J Clin Oncol 2010; 28: 3965-3972.
86. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008; 41: 98-107.
87. Vukelja S, Rugo H, Vogel C et al. A phase II study of trastuzumab-DM1, a first-in-class HER 2 antibody-drug conjugate, in patients with HER 2+ metastatic breast cancer. 31st Annual San Antonio Breast Cancer Symposium 2008; Abstr 33.
88. Krop I, Lo RP, Miller K et al. A phase II study of trastuzumab-DM1 (T-DM1), a novel HER 2 antibody-drug conjugate, in patientspreviously treated with lapatinib, trastuzumab, and chemotherapy. Cancer Res 2009; 69: 795s. Abstract 5090.
89. Hurvitz S, Dirix L, Kocsis J et al. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel in previously-untreated HER 2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter open-label phase II study (TDM4450g/B021976). Eur J Cancer 2011; 47: S330. Abstract 5001.
90. Dieras V, Harbeck N, Albain K et al. A phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER 2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract P3-14-01.
91. Blackwell KL, Miles D, Gianni L et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER 2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 30, 2012 (suppl; abstr LBA 1).
92. Scheuer W, Friess T, Burtscher H et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER 2-positive human xenograft tumor models. Cancer Res 2009; 69: 9330-9336.
93. Portera CC, Walshe JM, Rosing DR et al. Cardiac toxicity and efficacy oftrastuzumab combined with pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008; 14: 2710-2716.
94. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28: 1138-1144.
95. Gianni L, Pienkowski T, Im Y-H et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER 2-positive breast cancer (Neo-Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(1):25-32.
96. Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 12,366(2):109-119.
97. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010; 28: 1301-1307.
98. Hickish T, Wheatley D, Lin N et al. Use of BIB W 2992, a novel irreversible EG FR/HER 1 and HER 2 tyrosine kinase inhibitor to treat patients with HER 2-positive metastatic breast cancer after failure of treatment with trastuzumab. Cancer Res 2009; 69: 2191-2194. Abstract 5060.99.
99. Jäger M, Schoberth A, Ruf P et al. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res. 2009;69(10):4270-4276.
100. Bedard PL, de AE, Cardoso F. Beyond trastuzumab: overcoming resistance totargeted HER 2 therapy in breast cancer. Curr Cancer Drug Targets 2009; 9: 148-162.